Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma By Ogkologos - December 18, 2024 955 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer? August 20, 2024 105-Year-Old Woman Sets Record For 100-Meter Dash November 16, 2021 Drug Shows Promise in Slowing Progression of Smoldering Myeloma to Cancer June 7, 2019 Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor... March 26, 2024 Load more HOT NEWS Adding Upfront SRS to CNS-penetrant TKI Improves Time-to-CNS Progression and Local... Radiation Treatment Delivery Improved Using a Visualization of the Invisible Radiation... The Winter Solstice ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland
